IA Trial Radar

Discutamos y exploremos los ensayos clínicos con Chugai Pharmaceutical como patrocinador principal o colaborador.

Puedo ayudarle a entender sus condiciones de salud, tratamientos o encontrar ensayos clínicos cercanos.
Nuestra herramienta de búsqueda solo admite inglés. Para búsquedas y discusiones en otros idiomas, use la IA Trial Radar o seleccione los filtros de condición médica y ubicación a continuación.
24 ensayos clínicos
  
Título del estudio
Estado
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A (ZEBRHA 2) NCT07416604
Aún no recluta
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A (ZEBRHA 1) NCT07416526
Aún no recluta
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-2) NCT06819891
Reclutando
Estudio para evaluar la eficacia y la seguridad del tratamiento de inducción y mantenimiento con afimkibart (RO7790121) en participantes con enfermedad de Crohn de moderada a gravemente activa (SIBERITE-1) NCT06819878
Reclutando
Estudio para evaluar la eficacia y la seguridad de divarasib y pembrolizumab frente a pembrolizumab y pemetrexed y carboplatino o cisplatino en participantes con cáncer de pulmón no microcítico no escamoso avanzado o metastásico con mutación KRAS G12C no tratado previamente. (Krascendo 2) NCT06793215
Reclutando
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-1) NCT06589986
Activo, no reclutando
Estudio para evaluar la eficacia y la seguridad de divarasib frente a sotorasib o adagrasib en participantes con cáncer de pulmón no microcítico avanzado o metastásico con mutación KRAS G12C previamente tratado. (Krascendo 1) NCT06497556
Activo, no reclutando
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) (SKYSCRAPER-14) NCT05904886
Activo, no reclutando
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis (Cielo) NCT05503264
Reclutando
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) NCT05494619
Retirado
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (Meteoroid) NCT05271409
Reclutando
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (SAkuraBonsai) NCT05269667
TerminadoResultados publicados
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis NCT04963270
TerminadoResultados publicados
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-p) NCT04958265
Activo, no reclutando
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a) NCT04861259
Activo, no reclutando
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO) NCT04740931
CompletadoResultados publicados
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON) NCT04740905
CompletadoResultados publicados
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors (COMMODORE 2) NCT04434092
Activo, no reclutandoResultados publicados
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1) NCT04432584
Activo, no reclutando
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03) NCT04338269
TerminadoResultados publicados
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) NCT03726879
CompletadoResultados publicados
Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria (COMPOSER) NCT03157635
Activo, no reclutando
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4) NCT03020160
CompletadoResultados publicados
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3) NCT02847637
CompletadoResultados publicados